Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology
ORION CORPORATION PRESS RELEASE 25 SEPTEMBER 2024 at 15.00 EEST Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation...
Day: September 25, 2024
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose –...
Sofwave to Participate in the Jefferies Virtual Private MedTech Summit
SAN CLEMENTE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in...
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2...
Sensus Healthcare Sells SRT System to Providence Swedish Hospital
Continues customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancersBOCA RATON, Fla., Sept. 25, 2024...
Elixirgen Therapeutics Receives Rare Pediatric Disease Designation for EXG-34217 in Dyskeratosis Congenita and Related Telomere Biology Disorders
Elixirgen Therapeutics is currently enrolling patients in its Phase 1/2 trial evaluating EXG-34217 in patients with telomere biology disorders at...
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
DOYLESTOWN, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical...
Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent
– Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and...
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...
Amedisys has earned the 2023 SHPBest™ Patient Satisfaction Awards
BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice...
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their geneticsSUNNYVALE, Calif., Sept. 25,...
Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024
BEDFORD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed...
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE)...
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration Equivalent...
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025GAITHERSBURG, Md., Sept. 25, 2024...
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into...
New Research from the International Coaching Federation Highlights Trends in Workplace Burnout
- Demand for mental well-being support becoming widespread - LEXINGTON, Ky., Sept. 25, 2024 /PRNewswire/ -- New research, released today...
FONDAZIONE PRADA PRESENTS “PRESERVING THE BRAIN: A CALL TO ACTION” IN MILAN
MILAN, Sept. 25, 2024 /PRNewswire/ -- The new edition of "Preserving the Brain," part of Fondazione Prada's "Human Brains" project...
Compliancy Group is G2’s Fall 2024 Leader for Healthcare Compliance Software
NEW YORK, Sept. 25, 2024 /PRNewswire/ -- Compliancy Group has been awarded as G2's Fall Leader for Healthcare Compliance Software....
Cantargia Presents New Results at EADV 2024 Highlighting the Potential of CAN10 Treatment in Dermatology
LUND, SE / ACCESSWIRE / September 25, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from...